SAT0236 Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral Jak-1 Inhibitor in Patients With Rheumatoid Arthritis in an Open Label Extension Study
doi 10.1136/annrheumdis-2018-eular.7021
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2018
Authors
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism